Dianthus Therapeutics, Inc. /DE/

For the period ended Sep 30, 2026. Filed Nov 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 4, 2026

DNTH$86.03+3.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Other Information

Item 5. Other Information.

(c) Trading Plans. The following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act) or director who entered into, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the quarter ended September 30, 2026:

Name (Title)	Action Taken (Date of Action)	Nature of Trading Arrangement	Type of Trading Arrangement	Duration of Trading Arrangement	Aggregate Number of Securities
Ryan Savitz (Executive Vice President, Chief Financial Officer and Chief Business Officer)	Adoption (August 7, 2026)	Sale	Rule 10b5-1 trading arrangement	Through and including March 31, 2028	Up to 219,634
Adam Veness(Senior Vice President, General Counsel and Secretary)	Adoption (September 14, 2026)	Sale	Rule 10b5-1 trading arrangement	Through and including December 31, 2027	Up to 60,000

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.